1
|
Sedrakyan A, Marinac-Dabic D, Campbell B, Aryal S, Baird CE, Goodney P, Cronenwett JL, Beck AW, Paxton EW, Hu J, Brindis R, Baskin K, Cowley T, Levy J, Liebeskind DS, Poulose BK, Rardin CR, Resnic FS, Tcheng J, Fisher B, Viviano C, Devlin V, Sheldon M, Eldrup-Jorgensen J, Berlin JA, Drozda J, Matheny ME, Dhruva SS, Feeney T, Mitchell K, Pappas G. Advancing the Real-World Evidence for Medical Devices through Coordinated Registry Networks. BMJ Surg Interv Health Technologies 2022; 4:e000123. [PMID: 36393894 PMCID: PMC9660584 DOI: 10.1136/bmjsit-2021-000123] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Accepted: 12/31/2021] [Indexed: 11/16/2022] Open
Abstract
ObjectivesGenerating and using real-world evidence (RWE) is a pragmatic solution for evaluating health technologies. RWE is recognized by regulators, health technology assessors, clinicians, and manufacturers as a valid source of information to support their decision-making. Well-designed registries can provide RWE and become more powerful when linked with electronic health records and administrative databases in coordinated registry networks (CRNs). Our objective was to create a framework of maturity of CRNs and registries, so guiding their development and the prioritization of funding.Design, setting, and participantsWe invited 52 stakeholders from diverse backgrounds including patient advocacy groups, academic, clinical, industry and regulatory experts to participate on a Delphi survey. Of those invited, 42 participated in the survey to provide feedback on the maturity framework for CRNs and registries. An expert panel reviewed the responses to refine the framework until the target consensus of 80% was reached. Two rounds of the Delphi were distributed via Qualtrics online platform from July to August 2020 and from October to November 2020.Main outcome measuresConsensus on the maturity framework for CRNs and registries consisted of seven domains (unique device identification, efficient data collection, data quality, product life cycle approach, governance and sustainability, quality improvement, and patient-reported outcomes), each presented with five levels of maturity.ResultsOf 52 invited experts, 41 (79.9%) responded to round 1; all 41 responded to round 2; and consensus was reached for most domains. The expert panel resolved the disagreements and final consensus estimates ranged from 80.5% to 92.7% for seven domains.ConclusionsWe have developed a robust framework to assess the maturity of any CRN (or registry) to provide reliable RWE. This framework will promote harmonization of approaches to RWE generation across different disciplines and health systems. The domains and their levels may evolve over time as new solutions become available.
Collapse
Affiliation(s)
- Art Sedrakyan
- Department of Population Health Sciences; Medical Devices Epidemiology Network (MDEpiNet) Coordinating Center, Weill Cornell Medical College, New York, New York, USA
| | - Danica Marinac-Dabic
- Center for Devices and Radiological Health (CDRH), US Food and Drug Administration, Silver Spring, Maryland, USA
| | - Bruce Campbell
- Vascular Surgery, University of Exeter Medical School, Exter, UK
| | - Suvekshya Aryal
- Department of Population Health Sciences; Medical Devices Epidemiology Network (MDEpiNet) Coordinating Center, Weill Cornell Medical College, New York, New York, USA
| | - Courtney E Baird
- Health Services, Policy and Practice, Brown University School of Public Health, Providence, Rhode Island, USA
| | - Philip Goodney
- Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
| | - Jack L Cronenwett
- Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
| | - Adam W Beck
- Division of Vascular Surgery and Endovascular Therapy, University of Alabama, Birmingham, Alabama, USA
| | - Elizabeth W Paxton
- Surgical Outcomes and Analysis, Kaiser Permanente, Harbor City, California, USA
| | - Jim Hu
- Department of Urology, Weill Cornell Medical College, New York, New York, USA
| | - Ralph Brindis
- Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, California, USA
| | - Kevin Baskin
- Vascular and Interventional Radiology, Conemaugh Memorial Medical Center, Johnstown, Pennsylvania, USA
| | | | - Jeffery Levy
- Robotic Surgery, Institute of Surgical Excellence, Philadelphia, Pennsylvania, USA
| | - David S Liebeskind
- Department of Neurology, Stroke Center, University of California Los Angeles, Los Angeles, California, USA
| | - Benjamin K Poulose
- Center for Abdominal Core Health, Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Charles R Rardin
- Department of Obstetrics and Gyencology, Women and Infants Hospital of Rhode Island, Providence, Rhode Island, USA
| | - Frederic S Resnic
- Department of Cardiology, Comparative Effective Research Institute, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA
| | - James Tcheng
- Department of Medicine, Division of Cardiology, Duke University, Durham, North Carolina, USA
| | - Benjamin Fisher
- Center for Devices and Radiological Health (CDRH), US Food and Drug Administration, Silver Spring, Maryland, USA
| | - Charles Viviano
- Center for Devices and Radiological Health (CDRH), US Food and Drug Administration, Silver Spring, Maryland, USA
| | - Vincent Devlin
- Center for Devices and Radiological Health (CDRH), US Food and Drug Administration, Silver Spring, Maryland, USA
| | - Murray Sheldon
- Center for Devices and Radiological Health (CDRH), US Food and Drug Administration, Silver Spring, Maryland, USA
| | - Jens Eldrup-Jorgensen
- Vascular Surgery, Maine Medical Center, Portland, Maine, USA
- Surgery, Tufts University School of Medicine, Boston, Massachusetts, USA
| | - Jesse A Berlin
- Global Epidemiology, Johnson and Johnson Limited, New Brunswick, New Jersey, USA
| | - Joseph Drozda
- Outcomes Research, Mercy Health, St. Louis, Missouri, USA
| | - Michael E Matheny
- Department of Biomedical Informatics and Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Sanket S Dhruva
- Department of Medicine, University of California San Francisco School of Medicine, San Francisco, California, USA
| | - Timothy Feeney
- Department of Surgery, Boston University, Boston, Massachusetts, USA
| | | | - Gregory Pappas
- Center for Biologicals Evaluation and Research (CBER), US Food and Drug Administration, Silver Spring, Maryland, USA
| |
Collapse
|
2
|
Sambola A, Elola FJ, Buera I, Fernández C, Bernal JL, Ariza A, Brindis R, Bueno H, Rodríguez-Padial L, Marín F, Barrabés JA, Hsia R, Anguita M. Sex bias in admission to tertiary-care centres for acute myocardial infarction and cardiogenic shock. Eur J Clin Invest 2021; 51:e13526. [PMID: 33621347 DOI: 10.1111/eci.13526] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2020] [Revised: 01/17/2021] [Accepted: 02/21/2021] [Indexed: 12/16/2022]
Abstract
BACKGROUND There are limited data on sex-specific outcomes and management of cardiogenic shock complicating ST-segment elevation myocardial infarction (CS-STEMI). We investigated whether any sex bias exists in the admission to revascularization capable hospitals (RCH) or intensive cardiac care units (ICCU) and its impact on in-hospital mortality. METHODS We used the Spanish National Health System Minimum Basic Data from 2003 to 2015 to identify patients with CS-STEMI. The primary outcome was sex differences in in-hospital mortality. RESULTS Among 340 490 STEMI patients, 20 262 (6%) had CS and 29.2% were female. CS incidence was higher in women than in men (7.9% vs 5.1%, P = .001). Women were older and had more hypertension and diabetes, and were less often admitted to RCH than men (from 58.7% in 2003 to 79.6% in 2015; and from 61.9% in 2003 to 85.3% in 2015; respectively, P = .01), and to ICCU centres (25.7% vs 29.2%, P = .001). Adjusted mortality was higher in women than men over time (from 79.5 ± 4.3% to 65.8 ± 6.5%; and from 67.8 ± 6% to 58.1 ± 6.5%; respectively, P < .001). ICCU availability was associated with higher use of Percutaneous coronary intervention (PCI) in women (46.8% to 67.2%; P < .001) but was even higher in men (54.8% to 77.4%; P < .001). In ICCU centres, adjusted mortality rates decreased in both sexes, but lower in women (from 74.9 ± 5.4% to 66.3 ± 6.6%) than in men (from 67.8 ± 6.0% to 58.1 ± 6.5%, P < .001). Female sex was an independent predictor of mortality (OR 1.18 95% CI 1.10-1.27, P < .001). CONCLUSIONS Women with CS-STEMI were less referred to tertiary-care centres and had a higher adjusted in-hospital mortality than men.
Collapse
Affiliation(s)
- Antonia Sambola
- Department of Cardiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma, Barcelona, Spain.,Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma, Barcelona, Spain.,CIBER de enfermedades CardioVasculares (CIBER-CV), Barcelona, Spain
| | | | - Irene Buera
- Department of Cardiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma, Barcelona, Spain.,Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma, Barcelona, Spain.,CIBER de enfermedades CardioVasculares (CIBER-CV), Barcelona, Spain
| | - Cristina Fernández
- Foundation Institute for Healthcare Improvement, Madrid, Spain.,Department of Preventive Medicine, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - José Luis Bernal
- Foundation Institute for Healthcare Improvement, Madrid, Spain.,Universidad Complutense de Madrid, Madrid, Spain
| | - Albert Ariza
- CIBER de enfermedades CardioVasculares (CIBER-CV), Barcelona, Spain.,Heart Diseases Institute, Hospital Universitario de Bellvitge -IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Ralph Brindis
- Department of Medicine & The Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, USA
| | - Héctor Bueno
- CIBER de enfermedades CardioVasculares (CIBER-CV), Barcelona, Spain.,Management Control Department, Hospital Universitario 12 de Octubre, Madrid, Spain.,Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.,Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | - Francisco Marín
- Hospital Universitario Virgen de la Arrixaca, El Palmar, Spain
| | - José Antonio Barrabés
- Department of Cardiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma, Barcelona, Spain.,Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma, Barcelona, Spain.,CIBER de enfermedades CardioVasculares (CIBER-CV), Barcelona, Spain
| | - Renee Hsia
- Health Policy Studies in the Department of Emergency Medicine at University of California, San Francisco, CA, USA
| | - Manuel Anguita
- Department of Cardiology, Hospital Universitario Reina Sofía de Cordoba, Córdoba, Spain
| |
Collapse
|
3
|
Butala NM, Faridi KF, Secemsky EA, Song Y, Curtis J, Gibson CM, Brindis R, Shen C, Yeh RW. Comparing Baseline Data From Registries With Trials: Evidence From the CathPCI Registry and DAPT Study. JACC Cardiovasc Interv 2021; 14:1386-1388. [PMID: 34167685 DOI: 10.1016/j.jcin.2021.03.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2021] [Revised: 03/24/2021] [Accepted: 03/30/2021] [Indexed: 11/25/2022]
|
4
|
Forman DE, Maurer MS, Boyd C, Brindis R, Salive ME, Horne FM, Bell SP, Fulmer T, Reuben DB, Zieman S, Rich MW. Multimorbidity in Older Adults With Cardiovascular Disease. J Am Coll Cardiol 2018; 71:2149-2161. [PMID: 29747836 PMCID: PMC6028235 DOI: 10.1016/j.jacc.2018.03.022] [Citation(s) in RCA: 174] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2017] [Revised: 02/26/2018] [Accepted: 03/01/2018] [Indexed: 11/19/2022]
Abstract
Multimorbidity occurs in adults of all ages, but the number and complexity of comorbid conditions commonly increase with advancing age such that cardiovascular disease (CVD) in older adults typically occurs in a context of multimorbidity. Current clinical practice and research mainly target single disease-specific care that does not embrace the complexities imposed by concurrent conditions. In this paper, emerging concepts regarding CVD in combination with multimorbidity are reviewed, including recommendations for incorporating multimorbidity into clinical decision making, critical knowledge gaps, and research priorities to optimize care of complex older patients.
Collapse
Affiliation(s)
- Daniel E Forman
- Department of Medicine, Section of Geriatric Cardiology, Veterans Affairs Geriatric Research Education, and Clinical Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
| | - Mathew S Maurer
- Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, New York
| | - Cynthia Boyd
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Ralph Brindis
- Phillip R. Lee Institute for Health Policy Studies, University of California-San Francisco, San Francisco, California
| | - Marcel E Salive
- Division of Geriatrics and Clinical Gerontology, National Institute on Aging, Bethesda, Maryland
| | | | - Susan P Bell
- Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | | | - David B Reuben
- Division of Geriatrics, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
| | - Susan Zieman
- Division of Geriatrics and Clinical Gerontology, National Institute on Aging, Bethesda, Maryland
| | - Michael W Rich
- Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
| |
Collapse
|
5
|
Albert NM, Gluckman T, McNamara R, Fonarow GC, Malik A, Brindis R, Lu D, Roe M, Tingley J, Negi S, Goldberg LR, Rogers S, Mobayed J, Patel S, Pruski B, Hewitt K, Fanari Z, Lucas J. CHANGES IN HOSPITAL PERFORMANCE AND TRANSITION-CARE MEASURES 1-YEAR AFTER INITIATION OF THE PATIENT NAVIGATOR PROGRAM. J Am Coll Cardiol 2018. [DOI: 10.1016/s0735-1097(18)31196-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
6
|
Lewandowski TJ, Allen J, DeFranco A, Seals A, Fontanet H, Lohr N, Liberman J, Brindis R, Purow J, Gomez A, Phillips K, Wilson R, Ahmed M, Ranadive N, Groenewold S, Aranda J. UNLOCKING THE POWER OF DATA: INFORMATION TECHNOLOGY IMPLEMENTATION FOR SMARTER MANAGEMENT AND RESOURCE USE FOR TODAY'S COMPLEX CARE DELIVERY. J Am Coll Cardiol 2017. [DOI: 10.1016/s0735-1097(17)35885-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
7
|
Gurvitz M, Burns KM, Brindis R, Broberg CS, Daniels CJ, Fuller SMPN, Honein MA, Khairy P, Kuehl KS, Landzberg MJ, Mahle WT, Mann DL, Marelli A, Newburger JW, Pearson GD, Starling RC, Tringali GR, Valente AM, Wu JC, Califf RM. Emerging Research Directions in Adult Congenital Heart Disease: A Report From an NHLBI/ACHA Working Group. J Am Coll Cardiol 2016; 67:1956-64. [PMID: 27102511 DOI: 10.1016/j.jacc.2016.01.062] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Revised: 12/21/2015] [Accepted: 01/25/2016] [Indexed: 12/20/2022]
Abstract
Congenital heart disease (CHD) is the most common birth defect, affecting about 0.8% of live births. Advances in recent decades have allowed >85% of children with CHD to survive to adulthood, creating a growing population of adults with CHD. Little information exists regarding survival, demographics, late outcomes, and comorbidities in this emerging group, and multiple barriers impede research in adult CHD. The National Heart, Lung, and Blood Institute and the Adult Congenital Heart Association convened a multidisciplinary working group to identify high-impact research questions in adult CHD. This report summarizes the meeting discussions in the broad areas of CHD-related heart failure, vascular disease, and multisystem complications. High-priority subtopics identified included heart failure in tetralogy of Fallot, mechanical circulatory support/transplantation, sudden cardiac death, vascular outcomes in coarctation of the aorta, late outcomes in single-ventricle disease, cognitive and psychiatric issues, and pregnancy.
Collapse
Affiliation(s)
- Michelle Gurvitz
- Harvard Medical School, Boston Adult Congenital Heart and Pulmonary Hypertension Program, Boston Children's Hospital and Brigham and Women's Hospital, Boston, Massachusetts.
| | - Kristin M Burns
- National Heart, Lung, and Blood Institute, Bethesda, Maryland
| | | | | | | | | | | | - Paul Khairy
- Universite de Montreal, Montreal, Quebec, Canada
| | | | - Michael J Landzberg
- Harvard Medical School, Boston Adult Congenital Heart and Pulmonary Hypertension Program, Boston Children's Hospital and Brigham and Women's Hospital, Boston, Massachusetts
| | | | | | - Ariane Marelli
- McGill University Health Center, Montreal, Quebec, Canada
| | - Jane W Newburger
- Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts
| | - Gail D Pearson
- National Heart, Lung, and Blood Institute, Bethesda, Maryland
| | | | | | - Anne Marie Valente
- Harvard Medical School, Boston Adult Congenital Heart and Pulmonary Hypertension Program, Boston Children's Hospital and Brigham and Women's Hospital, Boston, Massachusetts
| | - Joseph C Wu
- Stanford University School of Medicine, Palo Alto, California
| | | |
Collapse
|
8
|
Tuzcu EM, Brennan JM, Brindis R, Carroll J, Edwards F, Grover F, Shahian D, Peterson E, Rumsfeld J, Holmes D, Mack M. TRANSCATHETER AORTIC VALVE IN VALVE REPLACEMENT FOR DEGENERATIVE AORTIC BIOPROSTHESIS: INITIAL RESULTS FROM THE STS/ACC TRANSCATHETER VALVE THERAPY REGISTRY. J Am Coll Cardiol 2014. [DOI: 10.1016/s0735-1097(14)61937-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Mack MJ, Brennan JM, Brindis R, Carroll J, Edwards F, Grover F, Shahian D, Tuzcu EM, Peterson ED, Rumsfeld JS, Hewitt K, Shewan C, Michaels J, Christensen B, Christian A, O'Brien S, Holmes D. Outcomes following transcatheter aortic valve replacement in the United States. JAMA 2013; 310:2069-77. [PMID: 24240934 DOI: 10.1001/jama.2013.282043] [Citation(s) in RCA: 370] [Impact Index Per Article: 33.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE Transcatheter aortic valve replacement (TAVR) was approved by the US Food and Drug Administration for the treatment of severe, symptomatic aortic stenosis and inoperable status (in 2011) and high-risk but operable status (starting in 2012). A national registry (the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy [STS/ACC TVT] Registry) was initiated to meet a condition for Medicare coverage and also facilitates outcome assessment and comparison with other trials and international registries. OBJECTIVE To report the initial US commercial experience with TAVR. DESIGN, SETTING, AND PARTICIPANTS We obtained results from all eligible US TAVR cases (n=7710) from 224 participating registry hospitals following the Edwards Sapien XT device commercialization (November 2011-May 2013). MAIN OUTCOMES AND MEASURES Primary outcomes included all-cause in-hospital mortality and stroke following TAVR. Secondary analyses included procedural complications and outcomes by clinical indication and access site. Device implantation success was defined as successful vascular access, deployment of a single device in the proper anatomic position, appropriate valve function without either moderate or severe AR, and successful retrieval of the delivery system. Thirty-day outcomes are presented for a representative 3133 cases (40.6%) at 114 centers with at least 80% complete follow-up reporting. RESULTS The 7710 patients who underwent TAVR included 1559 (20%) cases that were inoperable and 6151 (80%) cases that were high-risk but operable. The median age was 84 years (interquartile range [IQR], 78-88 years); 3783 patients (49%) were women and the median STS predicted risk of mortality was 7% (IQR, 5%-11%). At baseline, 2176 patients (75%) were either not at all satisfied (1297 patients [45%]) or mostly dissatisfied (879 patients [30%]) with their symptom status; 2198 (72%) had a 5-m walk time longer than 6 seconds (slow gait speed). The most common vascular access approach was transfemoral (4972 patients [64%]), followed by transapical (2197 patients [29%]) and other alternative approaches (536 patients [7%]); successful device implantation occurred in 7069 patients (92%; 95% CI, 91%-92%). The observed incidence of in-hospital mortality was 5.5% (95% CI, 5.0%-6.1%). Other major complications included stroke (2.0%; 95% CI, 1.7%-2.4%), dialysis-dependent renal failure (1.9%; 95% CI, 1.6%-2.2%), and major vascular injury (6.4%; 95% CI, 5.8%-6.9%). Median hospital stay was 6 days (IQR, 4-10 days), with 4613 (63%) discharged home. Among patients with available follow-up at 30 days (n=3133), the incidence of mortality was 7.6% (95% CI, 6.7%-8.6%) (noncardiovascular cause, 52%); a stroke had occurred in 2.8% (95% CI, 2.3%-3.5%), new dialysis in 2.5% (95% CI, 2.0%-3.1%), and reintervention in 0.5% (95% CI, 0.3%-0.8%). CONCLUSIONS AND RELEVANCE Among patients undergoing TAVR at US centers in the STS/ACC TVT Registry, device implantation success was achieved in 92% of cases, the overall in-hospital mortality rate was 5.5%, and the stroke rate was 2.0%. Although these postmarket US approval findings are comparable with prior published trial data and international experience, long-term follow-up is essential to assess continued efficacy and safety. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01737528.
Collapse
Affiliation(s)
- Michael J Mack
- Heart Hospital Baylor Plano, Baylor Healthcare System, Plano, Texas
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kotak K, Ambrose J, Singh M, Baghdasarian S, Mills P, Brindis R. PUBLIC REPORTING OF OUTCOMES AFFECTS PATIENT SELECTION FOR PCI IN PATIENTS WITH OUT-OF-HOSPITAL CARDIAC ARREST AND STEMI. J Am Coll Cardiol 2013. [DOI: 10.1016/s0735-1097(13)61550-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Hlatky MA, Solomon MD, Shilane D, Leong TK, Brindis R, Go AS. Use of Medications for Secondary Prevention After Coronary Bypass Surgery Compared With Percutaneous Coronary Intervention. J Am Coll Cardiol 2013; 61:295-301. [DOI: 10.1016/j.jacc.2012.10.018] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2012] [Revised: 10/06/2012] [Accepted: 10/22/2012] [Indexed: 12/17/2022]
|
12
|
Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, Daniel JG, Ekman I, Ho M, Johnson M, Kimmel SE, Liu LZ, Musaus J, Shrank WH, Whalley Buono E, Weiss K, Granger CB. Medication adherence: a call for action. Am Heart J 2011; 162:412-24. [PMID: 21884856 PMCID: PMC3947508 DOI: 10.1016/j.ahj.2011.06.007] [Citation(s) in RCA: 267] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2011] [Accepted: 06/15/2011] [Indexed: 12/30/2022]
Abstract
Poor adherence to efficacious cardiovascular-related medications has led to considerable morbidity, mortality, and avoidable health care costs. This article provides results of a recent think-tank meeting in which various stakeholder groups representing key experts from consumers, community health providers, the academic community, decision-making government officials (Food and Drug Administration, National Institutes of Health, etc), and industry scientists met to evaluate the current status of medication adherence and provide recommendations for improving outcomes. Below, we review the magnitude of the problem of medication adherence, prevalence, impact, and cost. We then summarize proven effective approaches and conclude with a discussion of recommendations to address this growing and significant public health issue of medication nonadherence.
Collapse
Affiliation(s)
- Hayden B Bosworth
- Center for Health Services Research in Primary Care, Durham VAMC, Durham, NC, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Affiliation(s)
- Ralph Brindis
- President, American College of Cardiology Washington, D.C. on behalf of the following organizations: American Association of Clinical Urologists, American Association of Neurological Surgeons, American Association of Neurology, American Association of Orthopaedic Surgeons, American College of Rheumatology, American Gastroenterological Association, American Medical Association, American Society of Echocardiography, American Society of Nuclear Cardiology, American Urological Association,
| |
Collapse
|
14
|
Brindis R, Gray HH. The ACC Looks Globally to Tackle Cardiovascular Disease. J Am Coll Cardiol 2011; 57:631-3. [DOI: 10.1016/j.jacc.2011.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
Brindis R, Goldberg SD, Turco MA, Dean LS. President's Page: Quality and Appropriateness of Care: The Response to Allegations and Actions Needed By the Cardiovascular Professional. J Am Coll Cardiol 2011; 57:111-3. [DOI: 10.1016/j.jacc.2010.12.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Brindis R, Spertus JA. President's Page: Employing Shared Decision-Making Models to Improve Care and Patient Value: A Cardiovascular Professional Initiative. J Am Coll Cardiol 2010; 56:2046-8. [DOI: 10.1016/j.jacc.2010.11.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Brindis R, Krumholz HM. President's page: national quality initiatives put ACC's mission into action. J Am Coll Cardiol 2010; 56:1260-2. [PMID: 20883935 DOI: 10.1016/j.jacc.2010.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
|
19
|
Brindis R, Harrington R. President's Page: The ACC Reconfirms Commitment to Transparent Relationships With Industry. J Am Coll Cardiol 2010; 56:900-2. [DOI: 10.1016/j.jacc.2010.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
|
21
|
Brindis R, Yancy C. President's Page: The American College of Cardiology and the American Heart Association: A Strong, Synergistic Partnership. J Am Coll Cardiol 2010; 55:2511-3. [DOI: 10.1016/j.jacc.2010.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
22
|
Brindis R. President's Page: Defending the Value of the Cardiovascular Professional. J Am Coll Cardiol 2010; 55:1998-2000. [DOI: 10.1016/j.jacc.2010.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Hendel RC, Cerqueira M, Douglas PS, Caruth KC, Allen JM, Jensen NC, Pan W, Brindis R, Wolk M. A multicenter assessment of the use of single-photon emission computed tomography myocardial perfusion imaging with appropriateness criteria. J Am Coll Cardiol 2010; 55:156-62. [PMID: 20117384 DOI: 10.1016/j.jacc.2009.11.004] [Citation(s) in RCA: 117] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2009] [Revised: 11/02/2009] [Accepted: 11/02/2009] [Indexed: 12/17/2022]
Abstract
OBJECTIVES The aim of this study was to assess the feasibility of evaluation for appropriate use of radionuclide myocardial perfusion imaging (MPI) in multiple clinical sites and to determine use patterns as well as identify areas of apparent inappropriate use. BACKGROUND Although cardiac imaging is highly valued for decision-making, the growth and expense related to these procedures has raised questions regarding overuse. The publication of appropriate use criteria (AUC), including those for MPI, were designed to provide guidance in the rational use of testing. However, limited data regarding the implementation and evaluation of AUC are available. METHODS Six diverse clinical sites enrolled consecutive patients undergoing MPI, collecting point-of-service data entered into an online form. An automated algorithm assigned a specific indication from the AUC that was classified as appropriate, uncertain, or inappropriate. Site-specific feedback was later provided to each practice on ordering patterns. RESULTS Of the 6,351 patients enrolled, 93% were successfully assigned an appropriateness level. Inappropriate use of MPI was found in 14.4% of patients, with a range of 4% to 22% among practices. Women and younger patients were more likely to undergo inappropriate MPI. Asymptomatic, low-risk patients accounted for 44.5% of inappropriate testing. Elimination of the 5 most common inappropriate use indications would reduce overall imaging volume by 13.2%. Inappropriate use by physicians from within the practice performing imaging was not greater than physicians outside of the practice. Educational feedback might have resulted in reduced inappropriate test ordering in 1 site. CONCLUSIONS The tracking of appropriate use is feasible in clinical practice, with an automated system that can readily identify practice patterns and targets for educational and quality improvement initiatives. This approach might provide an alternative to utilization management.
Collapse
|
24
|
Roe MT, Chen AY, Cannon CP, Rao S, Rumsfeld J, Magid DJ, Brindis R, Klein LW, Gibler WB, Ohman EM, Peterson ED. Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients supress ADverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. Circ Cardiovasc Qual Outcomes 2009; 2:414-20. [PMID: 20031871 DOI: 10.1161/circoutcomes.109.850248] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND The risks of late stent thrombosis with drug-eluting stents (DES) were intensely debated after the presentation of a number of studies highlighting this issue in September 2006. We evaluated trends in the use of DES for patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) from 2006 to 2008. METHODS AND RESULTS Temporal patterns of DES use were examined among non-ST-elevation myocardial infarction patients in the Can Rapid risk stratification of Unstable angina patients Supress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE; January 2006 to December 2006) and Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (ACTION-GWTG; January 2007 to June 2008) registries to determine how practice patterns changed for patients with acute myocardial infarction undergoing PCI. Among the 54 662 patients analyzed, the percentage of patients undergoing PCI by quarter varied from 54% to 58% during the analysis time period. More than 90% of patients undergoing PCI received a DES in the first 3 quarters of 2006 before the public debate about the risks of DES began. Thereafter, the use of DES for PCI patients declined during the fourth quarter of 2006 through the first quarter of 2007 (82% to 67%), gradually declined during quarters 2 to 4 of 2007 (63% to 63% to 59%) but then slightly increased from the first to second quarter of 2008 (58% to 60%). Hospital characteristics did not seem to correlate with temporal changes in DES use, but by the last 2 quarters of the study period, patient characteristics such as white race, hypertension, diabetes mellitus, and private or managed care insurance were more common among patients who received a DES compared with the beginning 2 quarters of the study period. CONCLUSIONS These findings highlight how rapidly treatment decisions in contemporary practice can be affected by public debate related to scientific presentations and publications.
Collapse
Affiliation(s)
- Matthew T Roe
- Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Douglas PS, Brennan JM, Anstrom KJ, Sedrakyan A, Eisenstein EL, Haque G, Dai D, Kong DF, Hammill B, Curtis L, Matchar D, Brindis R, Peterson ED. Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol 2009; 53:1629-41. [PMID: 19406337 DOI: 10.1016/j.jacc.2009.03.005] [Citation(s) in RCA: 123] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2009] [Revised: 03/05/2009] [Accepted: 03/09/2009] [Indexed: 11/25/2022]
Abstract
OBJECTIVES The aim of this study was to compare outcomes in older individuals receiving drug-eluting stents (DES) and bare-metal stents (BMS). BACKGROUND Comparative effectiveness of DES relative to BMS remains unclear. METHODS Outcomes were evaluated in 262,700 patients from 650 National Cardiovascular Data Registry sites during 2004 to 2006 with procedural registry data linked to Medicare claims for follow-up. Outcomes including death, myocardial infarction (MI), revascularization, major bleeding, stroke, death or MI, death or MI or revascularization, and death or MI or stroke were compared with estimated cumulative incidence rates with inverse probability weighted estimators and Cox proportional hazards ratios. RESULTS The DES were implanted in 217,675 patients and BMS were implanted in 45,025. At 30 months, DES patients had lower unadjusted rates of death (12.9% vs. 17.9%), MI (7.3 of 100 patients vs. 10.0 of 100 patients), and revascularization (23.0 of 100 patients vs. 24.5 of 100 patients) with no difference in stroke or bleeding. After adjustment, DES patients had lower rates of death (13.5% vs. 16.5%, hazard ratio [HR]: 0.75, 95% confidence interval [CI]: 0.72 to 0.79, p < 0.001) and MI (7.5 of 100 patients vs. 8.9 of 100 patients, HR: 0.77, 95% CI: 0.72 to 0.81, p < 0.001), with minimal difference in revascularization (23.5 of 100 patients vs. 23.4 of 100 patients; HR: 0.91, 95% CI: 0.87 to 0.96), stroke (3.1 of 100 patients vs. 2.7 of 100 patients, HR: 0.97, 95% CI: 0.88 to 1.07), or bleeding (3.4 of 100 patients vs. 3.6 of 100 patients, HR: 0.91, 95% CI: 0.84 to 1.00). The DES survival benefit was observed in all subgroups analyzed and persisted throughout 30 months of follow-up. CONCLUSIONS In this largest ever real-world study, patients receiving DES had significantly better clinical outcomes than their BMS counterparts, without an associated increase in bleeding or stroke, throughout 30 months of follow-up and across all pre-specified subgroups.
Collapse
Affiliation(s)
- Pamela S Douglas
- Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Tavris DR, Gallauresi BA, Dey S, Brindis R, Mitchel K. Risk of local adverse events by gender following cardiac catheterization. Pharmacoepidemiol Drug Saf 2007; 16:125-31. [PMID: 16981230 DOI: 10.1002/pds.1307] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
PURPOSE To assess the reason for the relative high risk of local complications for women following cardiac catheterization by evaluating the associations between gender, sheath size, and local adverse outcomes following cardiac catheterization. METHODS The data used in this study were obtained from a portion of the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR), which included 13 878 patients who underwent cardiac catheterization at one of 59 participating cardiac catheterization institutions throughout the United States during late 2003. Rates of serious local vascular adverse events were calculated by gender following cardiac catheterization, by type of vascular hemostasis used, stratified by arterial sheath size. RESULTS Serious local vascular events were reported in 3.54% of patients, most commonly hematoma (2.00%). The relative risk for women of any vascular complication was 1.40 [95%CI = 1.17, 1.67, p = 0.0002]. A statistically significant relative risk for woman was evident when collagen plug devices or manual compression alone were used as the first method for hemostasis. The rate of vascular complications increased progressively with increasing sheath size, more so in women than in men. CONCLUSIONS High relative risk for women of local vascular complications following cardiac catheterization was demonstrated with use of manual compression, as well as with collagen plug devices to control femoral artery bleeding. Large sheath size is associated with both a relatively high absolute risk and a high relative risk for women. Knowledge of this information should be considered by interventional cardiologists in making decisions on how to achieve hemostasis following cardiac catheterization.
Collapse
Affiliation(s)
- Dale R Tavris
- Food and Drug Administration, Center for Devices and Radiological Health Epidemiology Branch Gallauresi Beverly, MA, USA.
| | | | | | | | | |
Collapse
|
27
|
|
28
|
Chaparro S, Veledar E, Weintraub W, Brindis R, Aggarwal K. Periprocedural complications of sirolimus-eluting and paclitaxel-eluting stent use in patients undergoing intervention for diseased saphenous vein grafts. Cardiovascular Revascularization Medicine 2006. [DOI: 10.1016/j.carrev.2006.03.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
|
30
|
|
31
|
Hoekstra JW, Pollack CV, Roe MT, Peterson ED, Brindis R, Harrington RA, Christenson RH, Smith SC, Ohman EM, Gibler WB. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med 2002; 9:1146-55. [PMID: 12414463 DOI: 10.1111/j.1553-2712.2002.tb01569.x] [Citation(s) in RCA: 118] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Although acute coronary syndromes (ACS) represent a well-recognized source of morbidity and mortality for patients with cardiovascular disease, evidence-based therapies shown to improve outcomes for ACS are frequently underused in appropriate patients, especially in the emergency department (ED). Despite dissemination of expert recommendations from the American College of Cardiology/American Heart Association (ACC/AHA) and ED-focused recapitulation of them in the emergency medicine literature, significant barriers continue to limit the adoption of guidelines in clinical practice and appear to hinder the use of beneficial therapies and interventions in the ED. Unique and creative approaches are therefore needed to stimulate better adherence to practice guidelines and improve the quality of care for patients with non-ST-elevation myocardial infarction (NSTE) ACS. The CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines) quality improvement and educational initiative provides an innovative and multifaceted approach to the education of emergency physicians and cardiologists in the care of patients with NSTE ACS. The CRUSADE initiative is a multidisciplinary cooperative effort involving over 400 EDs and medical centers. It includes an ACS registry designed to characterize demographic patterns and risk stratification results in patients who meet diagnostic criteria for high-risk NSTE ACS. It also measures the use of ED treatment modalities including aspirin, heparin, beta-blockers, and platelet inhibitors as recommended in the ACC/AHA guidelines. The results of a given institution's treatment patterns will be reported back to the practitioners, with comparisons with national norms. These reports can be used as quality improvement tools to improve care at participating institutions. Beyond a static registry, these reports are coupled with educational efforts by the CRUSADE steering committee, scientific publications of risk stratification practice and success, as well as ED patterns of care, and tailored educational interventions, to reinforce compliance with the ACC/AHA guidelines. This initiative represents a truly innovative approach to improving care for ACS patients in the ED as well as on the cardiology service. This article describes the CRUSADE initiative and its implications for the practicing emergency physician. It is the intent of CRUSADE to improve patient care in the ED by tracking and encouraging compliance with evidence-based guidelines for the evaluation and management of NSTE ACS.
Collapse
|
32
|
|